Skip to content
cover image of November 2020 TAGline

TAGline November 2020

  • Dorrit Walsh
'The Struggle of a Lifetime' (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before us have advanced, despite myriad challenges and emerging new threats such as COVID-19.
Read more

Research in Action Awards 2020

  • Dorrit Walsh
Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progress and justice.
Read more
Cover image of A Landscape Analysis of HIV Cure-Related Clinical Research in 2019–Community Survey

A Landscape Analysis of HIV Cure-Related Clinical Research in 2019

  • Dorrit Walsh
In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.
Read more

In Memoriam – The Honorable John Lewis

  • Dorrit Walsh
Treatment Action Group (TAG) honors the titanic historic legacy and mourns the recent death of the Honorable John Lewis, U.S. Representative from the 5th Congressional district in Georgia and legendary civil rights leader.
Read more

Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020

  • Dorrit Walsh
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Read more
Back To Top